Hjem › Myelofibrose › Ohio
Myelofibrose kliniske forsøg i Ohio
17 studier for Myelofibrose søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Ohio State University, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07357727A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Cleveland Clinic, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07623161A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06661915Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Cleveland Clinic, Cleveland
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT05320198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Cincinnati, Cincinnati
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06343805Pacritinib Effectiveness in Real-world Settings
- The Ohio State University, Columbus
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT07774455A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. jul. 2026 · NCT06773195Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07441694Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 6. maj 2026 · NCT05835466Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
RekruttererFase 1
Alder 13 og opefter · Alle køn · Opdateret 5. maj 2026 · NCT04771572A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. apr. 2026 · NCT06034002A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. apr. 2026 · NCT06351631A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Cleveland Clinic, Cleveland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 12. feb. 2026 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Gabrail Cancer Center, Canton
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland
- og 3 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT06479135Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- Gabrail Cancer Center, Canton
- University of Cincinnati (UC), Cincinnati
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 21. feb. 2023 · NCT05280509Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.